The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Number 4: Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...